Leah Kuntz

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

The FDA has cleared the IND application for MIRA Pharmaceuticals' Ketamir-2, a promising oral treatment for neuropathic pain, which has shown superior efficacy and safety in preclinical studies.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Apnimed reveals promising results for AD109, a groundbreaking oral treatment for obstructive sleep apnea.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

Explore essential insights and best practices in geriatric psychiatry in our July theme! Submit your insights, tips, and case studies centered on healthy aging for older adults.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Check out the pipeline updates from June!

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

Christine Yu Moutier, MD, the chief medical officer of the AFSP, speaks about the impact of losing LGBTQ+ tailored crisis support via 988, and strategies to better support vulnerable youth.

Stay informed with this week's highlights, including more on the clozapine REMS, the termination of the 988 LGBTQ+ specific services, and the intersection of sex and psychiatry!

LGBTQ+ youth face increased suicide risks as vital support services are cut, prompting urgent calls for Congress to reverse this dangerous decision.

Ecopipam shows promise as a safe, effective treatment for Tourette syndrome in children and adolescents, significantly reducing tic severity and improving quality of life.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.